NCT04842617View on ClinicalTrials.gov

Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

5,274

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2031

Conditions

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

Interventions

DRUG

SHR6390

SHR6390 combined with endocrine therapy

DRUG

placebo

placebo combined with endocrine therapy

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04842617 - Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative | Biotech Hunter | Biotech Hunter